title: [Intravesical therapy: Influence on superficial bladder cancer progression].
abstract: OBJECTIVE
  To review the influence of various intravesical treatments on superficial bladder cancer progression.
  
  
  METHODS
  We retrospectively reviewed 473 superficial bladder neoplasias. Based on diagnosis and transurethral resection of bladder tumor (TUR BT), and depending on pathology, we proposed different treatment and follow-up schemes, with BCG in 139 cases and intravesical chemotherapy, mainly Mytomicin C, in 80.
  
  
  RESULTS
  Overall, the use or not of bladder instillations did not show statistically significant differences in time to progression. The use of intravesical therapy and maintenance therapy was an independent risk factor for disease-free time to progression when compared with induction.
  
  
  CONCLUSIONS
  The use of maintenance intravesical therapy with BCG resulted in a delayed progression of superficial bladder cancer, so that it seems the most effective treatment, mainly in moderate-high risk tumors.
authors.affiliation: Servicio de Urología I, Hospital Central de Asturias, Oviedo, Asturias, España. jgrmed@hotmail.com
authors.forename: Jorge
authors.initials: J
authors.lastname: García Rodríguez
authors.forename: Jesús María
authors.initials: JM
authors.lastname: Fernández Gómez
authors.forename: Safwan
authors.initials: S
authors.lastname: Escaf Barmadah
authors.forename: Miguel
authors.initials: M
authors.lastname: Alvarez Múgica
authors.forename: Laura
authors.initials: L
authors.lastname: Rodríguez Robles
authors.forename: José Luis
authors.initials: JL
authors.lastname: Martín Benito
authors.forename: Alfonso
authors.initials: A
authors.lastname: San Martín Blanco
authors.forename: Javier
authors.initials: J
authors.lastname: Regadera Sejas
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001500:BCG Vaccine / Q000008:administration & dosage*; D018450:Disease Progression; D006801:Humans; D016685:Mitomycin / Q000008:administration & dosage*; D012189:Retrospective Studies; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D001500:BCG Vaccine; D016685:Mitomycin